Similar articles

• Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

  Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V. Kalo E, et al. Mol Cell Biol. 2007 Dec;27(23):8228-42. doi: 10.1128/MCB.00374-07. Epub 2007 Sep 17. Mol Cell Biol. 2007. PMID: 17875924 Free PMC article.
• TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.

  Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. Zhu ML, et al. Prostate. 2008 Feb 15;68(3):287-95. doi: 10.1002/pros.20698. Prostate. 2008. PMID: 18163430
• Lentiviral-mediated Smad4 RNAi induced anti-proliferation by p16 up-regulation and apoptosis by caspase 3 down-regulation in hepatoma SMMC-7721 cells.

  Huang S, Zhang F, Miao L, Zhang H, Fan Z, Wang X, Ji G. Huang S, et al. Oncol Rep. 2008 Nov;20(5):1053-9. Oncol Rep. 2008. PMID: 18949401
• Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.

  Fukuda M, Kurosaki H, Sairenji T. Fukuda M, et al. J Med Virol. 2006 Nov;78(11):1456-64. doi: 10.1002/jmv.20719. J Med Virol. 2006. PMID: 16998876
• Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate.

  Danielpour D. Danielpour D. Eur J Cancer. 2005 Apr;41(6):846-57. doi: 10.1016/j.ejca.2004.12.027. Eur J Cancer. 2005. PMID: 15808954 Review.